Elsevier

The Lancet

Volume 301, Issue 7806, 7 April 1973, Pages 735-737
The Lancet

CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITIS

https://doi.org/10.1016/S0140-6736(73)92125-9Get rights and content

Abstract

A double-blind prospective trial of prednisone versus azathioprine in the treatment of forty-seven patients with active chronic hepatitis over a 2-year period showed that prednisone was superior at improving liver function, preventing the development of œsophageal varices, and prolonging survival. However, side-effects with prednisone (15 mg. per day) were troublesome and sometimes serious.

References (18)

  • S.P. Mistilis et al.

    Am. J. Med.

    (1970)
  • R.D. Soloway et al.

    Gastroenterology

    (1972)
  • A.R. Page et al.

    Am. J. Med.

    (1964)
  • J. de Groote et al.

    Lancet

    (1968)
  • G.P. Lewis et al.

    Lancet

    (1971)
  • C.G. Mitchell et al.

    Lancet

    (1970)
  • G.C. Cook et al.

    Jl Med.

    (1971)
  • S.P. Mistilis et al.

    Australas. Ann. Med.

    (1967)
There are more references available in the full text version of this article.

Cited by (383)

  • Treatment of Autoimmune Hepatitis

    2024, Clinics in Liver Disease
  • Current paradigm and treatment options for autoimmune hepatitis

    2023, Comprehensive Guide to Hepatitis Advances
  • Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis

    2022, JHEP Reports
    Citation Excerpt :

    Corticosteroids alone or in combination with azathioprine (AZA) is recommended as the standard first-line treatment option. However, this recommendation is still based on trials conducted in the past 5 decades with the last published 26 years ago.5–10 The aims of treatment are to achieve complete biochemical response (CBR; normal IgG and aminotransferases) and remission of the disease (modified hepatitis activity index [mHAI] <4).

View all citing articles on Scopus
View full text